Skip to main content

Pentobarbital Dosage

Medically reviewed by Drugs.com. Last updated on Nov 23, 2023.

Applies to the following strengths: 50 mg/mL; 100 mg; 18.2 mg/5 mL; 120 mg; 60 mg; 50 mg; 200 mg; 30 mg; sodium

Usual Adult Dose for Insomnia

IM: 150 to 200 mg IM ONCE
IV:


Comments:

Uses:

Usual Adult Dose for Sedation

IM: 150 to 200 mg IM ONCE
IV:


Comments:

Uses:

Usual Adult Dose for Status Epilepticus

IM: 150 to 200 mg IM ONCE
IV:


Comments:

Uses:

Usual Pediatric Dose for Insomnia

Adequate, well-controlled studies have not been performed in pediatric patients; published case reports and other studies in pediatric patients supports safety and efficacy. Manufacturer suggested dosing:
IM: 2 to 6 mg/kg IM ONCE

IV: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Comments:

Uses:

Usual Pediatric Dose for Sedation

Adequate, well-controlled studies have not been performed in pediatric patients; published case reports and other studies in pediatric patients supports safety and efficacy. Manufacturer suggested dosing:
IM: 2 to 6 mg/kg IM ONCE

IV: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Comments:

Uses:

Usual Pediatric Dose for Status Epilepticus

Adequate, well-controlled studies have not been performed in pediatric patients; published case reports and other studies in pediatric patients supports safety and efficacy. Manufacturer suggested dosing:
IM: 2 to 6 mg/kg IM ONCE

IV: Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Comments:

Uses:

Renal Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Liver Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.

Dose Adjustments

Patients who are elderly and/or debilitated: The dose should be reduced because these patients may be more sensitive to barbiturates.

Withdrawal regimens: Cautious and gradual withdrawal of this drug should be performed over an extended period. The manufacturer product information should be consulted regarding recommendations for specific dosing regimens.

Precautions

CONTRAINDICATIONS:


Safety and efficacy of this drug have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule II

Dialysis

Data not available

Other Comments

Administration advice:


IV compatibility:

General:

Monitoring:

Patient advice:
for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Patients should report any behavior of concern to their healthcare provider as soon as possible.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.